Log in
AGA

AGA 2024 living guideline: drug therapy for moderate-to-severe ulcerative colitis

This AGA living guideline gives recommendations on choosing advanced therapies (biologics and small molecules) for adults with moderate-to-severe ulcerative colitis, including positioning of agents in biologic-naive and biologic-experienced patients. It is designed as a 'living' document that is updated as new trial data on newer agents (such as JAK inhibitors and S1P receptor modulators) become available, rather than a fixed periodic revision.

AGA2024 editionSummary
Official guidelineAGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. AGA, 2024.
Read the official guideline · Checked for a newer edition on 2026-10-20
We do not reproduce the guideline text — this page is an independent summary.

Who it applies to

Adults with moderate-to-severe ulcerative colitis being considered for or already on advanced pharmacological therapy, in specialist gastroenterology care.

Key recommendations

  • In biologic-naive patients, infliximab, vedolizumab, and ustekinumab are all reasonable first-line advanced therapy options, with comparable efficacy expectations.
  • Upadacitinib is recommended as an effective option in biologic-experienced patients, including those who have failed anti-TNF therapy.
  • The guideline favors avoiding routine use of older, less effective agents when newer biologics or small molecules are accessible for moderate-to-severe disease.
  • Combination therapy with an immunomodulator may be considered alongside infliximab to improve durability of response, particularly in biologic-naive patients.
  • Treatment choice should account for safety considerations, including cardiovascular and thromboembolic risk factors when considering JAK inhibitors.
  • Early escalation to advanced therapy is favored over prolonged corticosteroid courses in patients with moderate-to-severe disease.
  • Therapeutic drug monitoring concepts are acknowledged as relevant to optimizing anti-TNF therapy, though not detailed as a rigid protocol.
  • Patient preferences, comorbidities, and route of administration (IV vs subcutaneous vs oral) should inform shared decision-making on agent selection.

What is new in this edition

  • Incorporation of newer agents and updated comparative efficacy data as a 'living' guideline format rather than a single static update
  • Expanded guidance incorporating upadacitinib positioning in biologic-experienced patients

Practice points for students

  • Think of this as a continuously updated guideline rather than a one-time publication; recommendations may be revised as new trial data emerge.
  • Biologic-naive status is a key branch point for choosing initial advanced therapy.
  • JAK inhibitor safety signals (cardiovascular, thrombosis) are relevant when selecting therapy, especially in older patients or those with risk factors.
  • Advanced therapy is preferred over prolonged steroid dependence in moderate-to-severe UC.

Condition

Ulcerative colitis

Other guidelines on this topic

Independent educational summary written by the WhiteCoat Pro editorial team with AI assistance and checked by a second AI model. It does not reproduce the guideline text, tables or figures, and it is not affiliated with or endorsed by AGA. It is not medical advice: always read the original guideline before applying it to patients.